Item 8.01 Other Events.

On January 5, 2023, Zai Lab Limited (the "Company"), together with its partner NovoCure Limited ("Novocure"), issued a press release announcing that Novocure's LUNAR study, evaluating the safety and efficacy of Tumor Treating Fields together with standard therapies for stage 4 non-small cell lung cancer, met its primary overall survival endpoint. The Company has an exclusive license from Novocure to develop and commercialize Tumor Treating Fields in mainland China, Hong Kong, Macau, and Taiwan.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.                                             Description

99.1                     Press Release issued by Zai Lab Limited on January 5, 2023

104                    The cover page of this Current Report on Form 8-K is formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses